CRISPR-mediated knockout of VEGFR2/KDR inhibits cell growth in a squamous thyroid cancer cell line.

Squamous and anaplastic thyroid cancers are the most aggressive and life-threatening cancer types in humans, with the involvement of lymph nodes in 59% of cases and distant metastases in 26% of cases of all thyroid cancers. The median survival of squamous thyroid cancer patients is < 8 months and therefore is of high clinical concern. Here, we show that both VEGFC and VEGFR2/KDR are overexpressed in thyroid cancers, indicating that VEGF/VEGFR signaling plays a carcinogenic role in thyroid cancer development. Using CRISPR/Cas9, we established a KDR knockout (KO) SW579 squamous thyroid cancer cell line that exhibited dramatically decreased colony formation and invasion abilities (30% and 60% reduction, respectively) when compared to scrambled control cells. To validate the potential of KDR as a therapeutic target for thyroid cancers, we used the KDR RTK inhibitor sunitinib. Protein analysis and live/dead assay were performed to demonstrate that sunitinib significantly inhibited cell growth signal transduction and induced cell apoptosis of SW579 cells. These results suggest that selective targeting of KDR may have potential for development into novel anti-cancer therapies to suppress VEGF/VEGFR-mediated cancer development in patients with clinical advanced thyroid cancer.

Platelet-Derived Growth Factor Receptor-α Subunit Targeting Suppresses Metastasis in Advanced Thyroid Cancer In Vitro and In Vivo.

Thyroid cancer is the most common endocrine malignancy. Patients with well-differentiated thyroid cancers, such as papillary and follicular cancers, have a favorable prognosis. However, poorly differentiated thyroid cancers, such as medullary, squamous and anaplastic advanced thyroid cancers, are very aggressive and insensitive to radioiodine treatment. Thus, novel therapies that attenuate metastasis are urgently needed. We found that both PDGFC and PDGFRA are predominantly expressed in thyroid cancers and that the survival rate is significantly lower in patients with high PDGFRA expression. This finding indicates the important role of PDGF/PDGFR signaling in thyroid cancer development. Next, we established a SW579 squamous thyroid cancer cell line with 95.6% PDGFRA gene insertion and deletions (indels) through CRISPR/Cas9. Protein and invasion analysis showed a dramatic loss in EMT marker expression and metastatic ability. Furthermore, xenograft tumors derived from PDGFRA geneedited SW579 cells exhibited a minor decrease in tumor growth. However, distant lung metastasis was completely abolished upon PDGFRA gene editing, implying that PDGFRA could be an effective target to inhibit distant metastasis in advanced thyroid cancers. To translate this finding to the clinic, we used the most relevant multikinase inhibitor, imatinib, to inhibit PDGFRA signaling. The results showed that imatinib significantly suppressed cell growth, induced cell cycle arrest and cell death in SW579 cells. Our developed noninvasive apoptosis detection sensor (NIADS) indicated that imatinib induced cell apoptosis through caspase-3 activation. In conclusion, we believe that developing a specific and selective targeted therapy for PDGFRA would effectively suppress PDGFRA-mediated cancer aggressiveness in advanced thyroid cancers.

Series of Water-Stable Lanthanide Metal-Organic Frameworks Based on Carboxylic Acid Imidazolium Chloride: Tunable Luminescent Emission and Sensing.

A series of isomorphic lanthanide metal-organic frameworks (Ln-MOFs), {[Ln(L)(H2O)2]·5H2O}n (1-Ln, where Ln = Eu, Tb, Gd, and EuxTb1-x), have been synthesized by a rigid 1,3-bis(3,5-dicarboxyphenyl)imidazolium chloride (H4L+Cl-) ligand and Ln3+ ions via a solvothermal method. Single-crystal X-ray diffraction indicated that 1-Ln exhibited similar three-dimensional porous frameworks with one-dimensional channels decorated by the uncoordinated carboxylate oxygen atoms. The luminescent sensing studies indicated that 1-Eu is an outstanding reusable luminescent probe suitable for the simultaneous detection of Cr2O72-, CrO42-, and MnO4- ions in an aqueous solution. Remarkably, the different proportions of Eu3+ and Tb3+ can be combined into the same Ln-MOF to yield a new series of differently doped 1-EuxTb1-x MOFs. At the same excitation wavelength, they generated dual-emission peaks of Eu3+ and Tb3+ to show a gradual change in luminous color between yellow-green, yellow, orange, orange-red, and red. On the basis of the excellent optical properties of 1-Ln complexes, they can be employed as promising luminescent probe and multicolor tunable photoluminescence materials.

Five new 3D transition MOFs based on 1-(3,5-dicarboxylatobenzyl)-3,5-pyrazole dicarboxylic acid displaying unique luminescence sensing towards Fe3+ and magnetic properties.

Five new 3D MOFs: {[Zn3(HL)2H2O]·4H2O}n (1), {[Ba2L5H2O]·2H2O}n (2), {[Ba4(L)2·5H2O]·2H2O}n (3), {[Cd3(HL)2·Cl2·2H2O]·2H2O}n (4) and {[Cu2(L)2·2H2O]·4H2O}n (5), were constructed based on 1-(3,5-dicarboxylatobenzyl)-3,5-pyrazole dicarboxylic acid. Structural analysis shows that 1-5 have 3D frameworks, among which 1(Zn) exhibits high luminescence sensing for Fe3+ ions, excellent framework stability and reusability. The sensing mechanism of 1(Zn) is briefly discussed. In addition, 5(Cu) displays antiferromagnetic exchange phenomena.

Thiol-Functionalized Pores via Post-Synthesis Modification in a Metal-Organic Framework with Selective Removal of Hg(II) in Water.

Owing to the rapid increase of Hg(II) ions in water resources, the design and development of new adsorbents for Hg(II) removal are becoming a significant challenge in environmental protection. Herein, a thiol-functionalized metal-organic framework (SH-MiL-68(In)) was successfully prepared through a post-synthesis modification procedure, and the framework intactness and porosity were well maintained after this process. SH-MiL-68(In) exhibited selective adsorption performance for Hg(II) ions in water. Meanwhile, SH-MiL-68(In) also shows a high adsorption capacity (450 mg g-1), large adsorption rate (rate constant k2 = 1.25 g mg-1 min-1), and good recycling of adsorption capacity toward Hg(II) ions. The excellent adsorption performance resulted from the strong binding interactions between -SH soft basic groups and Hg(II) soft acidic ions.

A new stable luminescent Cd(ii) metal-organic framework with fluorescent sensing and selective dye adsorption properties.

A new luminescent metal-organic framework, {[Cd3(HL)2(H2O)3]·3H2O·2CH3CN}n (1) (H4L = 1-(3,5-dicarboxylatobenzyl)-3,5-pyrazole dicarboxylic acid), has been synthesized by solvothermal reaction and characterized by infrared spectroscopy, powder X-ray diffraction, thermogravimetry measurements and so on. 1 shows a new trinodal (4,4,6)-connected topology. Importantly, 1 displays intense luminescence in the solid state and high luminescent sensitivity and selectivity for Fe3+, CrO42- and Cr2O72- ions in aqueous solution, making it a potential probe for detecting these substances. The quenching mechanisms are also further discussed in detail. In addition, further research on the adsorption of dyes shows that 1 can selectively adsorb Congo red dye from other dye molecules.

CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic Thyroid Cancer.

Anaplastic carcinoma of the thyroid (ATC), also called undifferentiated thyroid cancer, is the least common but most aggressive and deadly thyroid gland malignancy of all thyroid cancers. The aim of this study is to explore essential biomarker and use CRISPR/Cas9 with lentivirus delivery to establish a gene-target therapeutic platform in ATC cells. At the beginning, the gene expression datasets from 1036 cancers from CCLE and 8215 tumors from TCGA were collected and analyzed, showing EGFR is predominantly overexpressed in thyroid cancers than other type of cancers (P = 0.017 in CCLE and P = 0.001 in TCGA). Using CRISPR/Cas9 genomic edit system, ATC cells with EGFR sgRNA lentivirus transfection obtained great disruptions on gene and protein expression, resulting in cell cycle arrest, cell growth inhibition, and most importantly metastasis turn-off ability. In addition, the FDA-approved TKI of afatinib for EGFR targeting also illustrates great anticancer activity on cancer cell death occurrence, cell growth inhibition, and cell cycle arrest in SW579 cells, an EGFR expressing human ATC cell line. Furthermore, off-target effect of using EGFR sgRNAs was measured and found no genomic editing can be detected in off-target candidate gene. To conclude, this study provides potential ATC therapeutic strategies for current and future clinical needs, which may be possible in increasing the survival rate of ATC patients by translational medicine.